Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss

被引:42
作者
Anastassopoulou, Cleo G.
Marozsan, Andre J.
Matet, Alexandre
Snyder, Amy D.
Arts, Eric J.
Kuhmann, Shawn E. [1 ]
Moore, John P.
机构
[1] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, Ithaca, NY 14853 USA
[2] Case Western Reserve Univ, Dept Med, Div Infect Dis, Cleveland, OH 44106 USA
关键词
D O I
10.1371/journal.ppat.0030079
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Fitness is a parameter used to quantify how well an organism adapts to its environment; in the present study, fitness is a measure of how well strains of human immunodeficiency virus type 1 (HIV-1) replicate in tissue culture. When HIV-1 develops resistance in vitro or in vivo to antiretroviral drugs such as reverse transcriptase or protease inhibitors, its fitness is often impaired. Here, we have investigated whether the development of resistance in vitro to a small molecule CCR5 inhibitor, AD101, has an associated fitness cost. To do this, we developed a growth-competition assay involving dual infections with molecularly cloned viruses that are essentially isogenic outside the env genes under study. Real-time TaqMan quantitative PCR (QPCR) was used to quantify each competing virus individually via probes specific to different, phenotypically silent target sequences engineered within their vif genes. Head-to-head competition assays of env clones derived from the AD101 escape mutant isolate, the inhibitor-sensitive parental virus, and a passage control virus showed that AD101 resistance was not associated with a fitness loss. This observation is consistent with the retention of the resistant phenotype when the escape mutant was cultured for a total of 20 passages in the absence of the selecting compound. Amino acid substitutions in the V3 region of gp120 that confer complete AD101 resistance cause a fitness loss when introduced into an AD101-sensitive, parental clone; however, in the resistant isolate, changes elsewhere in env that occurred prior to the substitutions within V3 appear to compensate for the adverse effect of the V3 changes on replicative capacity. These in vitro studies may have implications for the development and management of resistance to other CCR5 inhibitors that are being evaluated clinically for the treatment of HIV-1 infection.
引用
收藏
页码:720 / 732
页数:13
相关论文
共 46 条
[1]   PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE [J].
ADACHI, A ;
GENDELMAN, HE ;
KOENIG, S ;
FOLKS, T ;
WILLEY, R ;
RABSON, A ;
MARTIN, MA .
JOURNAL OF VIROLOGY, 1986, 59 (02) :284-291
[2]  
Armand-Ugón M, 2003, ANTIVIR THER, V8, P1
[3]   Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652 [J].
Baba, Masanori ;
Miyake, Hiroshi ;
Wang, Xin ;
Okamoto, Mika ;
Takashima, Katsunori .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (02) :707-715
[4]   Influence of sequence identity and unique breakpoints on the frequency of intersubtype HIV-1 recombination [J].
Baird, Heather A. ;
Gao, Yong ;
Galetto, Roman ;
Lalonde, Matthew ;
Anthony, Reshma M. ;
Giacomoni, Veronique ;
Abreha, Measho ;
Destefano, Jeffrey J. ;
Negroni, Matteo ;
Arts, Eric J. .
RETROVIROLOGY, 2006, 3 (1)
[5]   Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C [J].
Ball, SC ;
Abraha, A ;
Collins, KR ;
Marozsan, AJ ;
Baird, H ;
Quiñones-Mateu, ME ;
Penn-Nicholson, A ;
Murray, M ;
Richard, N ;
Lobritz, M ;
Zimmerman, PA ;
Kawamura, T ;
Blauvelt, A ;
Arts, EJ .
JOURNAL OF VIROLOGY, 2003, 77 (02) :1021-1038
[6]   Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults [J].
Barbour, JD ;
Wrin, T ;
Grant, RM ;
Martin, JN ;
Segal, MR ;
Petropoulos, CJ ;
Deeks, SG .
JOURNAL OF VIROLOGY, 2002, 76 (21) :11104-11112
[7]   HIV-1 REVERSE TRANSCRIPTION - A TERMINATION STEP AT THE CENTER OF THE GENOME [J].
CHARNEAU, P ;
MIRAMBEAU, G ;
ROUX, P ;
PAULOUS, S ;
BUC, H ;
CLAVEL, F .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 241 (05) :651-662
[8]   Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants [J].
Collins, JA ;
Thompson, MG ;
Paintsil, E ;
Ricketts, M ;
Gedzior, J ;
Alexander, L .
JOURNAL OF VIROLOGY, 2004, 78 (02) :603-611
[9]   Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus [J].
de Ronde, A ;
van Dooren, M ;
van der Hoek, L ;
Bouwhuis, D ;
de Rooij, E ;
van Gemen, B ;
de Boer, R ;
Goudsmit, J .
JOURNAL OF VIROLOGY, 2001, 75 (02) :595-602
[10]   Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. [J].
Deeks, SG ;
Wrin, T ;
Liegler, T ;
Hoh, R ;
Hayden, M ;
Barbour, JD ;
Hellmann, NS ;
Petropoulos, CJ ;
McCune, JM ;
Hellerstein, MK ;
Grant, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :472-480